KADIAN 10 MG
MORPHINE SULFATE : 10 MG · DIN 02242163 · BGP PHARMA ULC
Health Canada status: MARKETED
What is KADIAN?
KADIAN 10 MG contains MORPHINE SULFATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02242163, held by BGP PHARMA ULC, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 26-May-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KADIAN used for?
KADIAN (Morphine Sulfate Extended-Release Capsules) is indicated in adults for: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid-responsive; and for which alternative options are inadequate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is KADIAN called?
The same molecule, MORPHINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| MS Contin | Latin | Australia |
| Morphine Juno | Latin | Australia |
| Kapanol | Latin | Australia |
| MS Mono | Latin | Australia |
| Anamorph | Latin | Australia |
| Sevredol | Latin | Australia, Morocco |
| Morphine Phebra | Latin | Australia |
| MOSCONTIN | Latin | Morocco |
| MORPHINE | Latin | Morocco |
| OPIUM CAMPHORATED TINCT | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02242163 |
|---|---|
| Brand name | KADIAN |
| Generic / active ingredient | MORPHINE SULFATE : 10 MG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 10 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA01 MORPHINE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-May-2016 |
| Original market date | 2001-12-11 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02242163 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242163 |
| Brand name | KADIAN |
| Active ingredient / INN | MORPHINE SULFATE : 10 MG |
| ATC code | N02AA01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:08.08 |
| Health Canada schedule | NARCOTICS (CDSA I) |
| Biosimilar biologic | No |
| Market authorization holder | BGP PHARMA ULC |
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route | ORAL |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is MORPHINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AA01 MORPHINE. 56 of 172 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOLORAL SIROP | 1 MG | SYRUP | LABORATOIRE ATLAS INC | MARKETED | DIN 00614491 |
| DOLORAL SIROP | 5 MG | SYRUP | LABORATOIRE ATLAS INC | MARKETED | DIN 00614505 |
| KADIAN | 100 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02184451 |
| KADIAN | 20 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02184435 |
| KADIAN | 200 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02559722 |
| KADIAN | 50 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02184443 |
| M-EDIAT | 10 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320428 |
| M-EDIAT | 20 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320436 |
| M-EDIAT | 30 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320444 |
| M-EDIAT | 5 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320398 |
Who else supplies MORPHINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MORPHINE appears in 167 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does MORPHINE cost around the world?
MORPHINE is listed on 5 national price registers Nexara tracks, across 109 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 13 | 80 | 08 Sep 2026 |
| United Kingdom | hospital | 11 | 11 | 31 Aug 2026 |
| Morocco | PPV (public price) | 4 | 8 | 05 Sep 2026 |
| South Africa | single exit price | 8 | 8 | 01 Sep 2026 |
| United States | acquisition | 2 | 2 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.